- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02471794
Personalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot Study
January 23, 2017 updated by: Duke University
Personalized Health Planning in Shared Medical Appointments for Individuals With Type II
The primary aim of this study is to examine the feasibility of implementing an evidence based patient engagement strategy, known as personalized health planning (PHP), in the context of a a shared medical appointment (SMA) for individuals with type II diabetes in a primary care setting.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
All data for the prospective portion of this study was done being collected in September 2016.
The retrospective chart review will collect data up until March of 2017 (six months after the last subject completed the prospective phase by attending their last SMA session).
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Family Medicine Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A diagnosis of Type 2 diabetes within the last year
- A current patient at Duke Family Medicine.
- An A1C score greater than 7 and less than 14.
Exclusion Criteria:
- A diagnosis of Pre-diabetes
- A diagnosis of Type I diabetes
- Individuals with amputations as a result of their diabetes are excluded form this study.
- Individuals with renal dialysis will not be included in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Standard Shared Medical Appointment
The SMA group will be a standard shared diabetes medical appointment group consisting of up to 10 patients that utilizes the design and curriculum of the SMAs that are currently being held at the Duke Family Medicine Center.
|
|
|
Experimental: Personalized Health Planning Shared Medical Appointment
The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment.
Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session.
The participant notebook also includes educational handouts and worksheets to complement the educational curriculum.
|
The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment.
Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session.
The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
|
|
No Intervention: Retrospective
A retrospective chart review will be conducted once all participants (both SMA group and PHP SMA group) complete the intervention.
The retrospective chart review will collect healthcare utilization data six months prior, during, and after each subject's participation in the SMA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Feasibility measured using a patient satisfaction survey
Time Frame: 12 months
|
12 months
|
|
Change in patient activation measured using the patient activation measure
Time Frame: baseline; 6 months; 12 months
|
baseline; 6 months; 12 months
|
|
Change in self-management of diabetes self-efficacy using the Diabetes Empowerment Scale
Time Frame: baseline; 6 months; 12 months
|
baseline; 6 months; 12 months
|
|
Change in diabetes self efficacy using the 1-item diabetes self-efficacy scale
Time Frame: baseline; 6 months; 12 months
|
baseline; 6 months; 12 months
|
|
Change in A1C using the A1C blood test
Time Frame: baseline; 3 months; 6 months; 9 months; 12 months
|
baseline; 3 months; 6 months; 9 months; 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in depression screening score using the Patient Health Questionnaire (PHQ-9)
Time Frame: baseline; 6 months; 12 months
|
baseline; 6 months; 12 months
|
|
Change in functional health and well-being using the short form health survey
Time Frame: baseline; 6 months; 12 months
|
baseline; 6 months; 12 months
|
|
Change in general self-rated health using the general self rated health survey (GSRH)
Time Frame: baseline; 6 months; 12 months
|
baseline; 6 months; 12 months
|
|
Change in health goal progress using a goal progress visual analog scale
Time Frame: 3 months; 10 months
|
3 months; 10 months
|
|
change in body mass index using weight and height measurements
Time Frame: baseline; 1 months; 2 months; 3 months; 5 months; 8 months; 10 months; 12 months
|
baseline; 1 months; 2 months; 3 months; 5 months; 8 months; 10 months; 12 months
|
|
change in blood pressure using blood pressure measurement
Time Frame: baseline; 1 months; 2 months; 3 months; 5 months; 8 months; 10 months; 12 months
|
baseline; 1 months; 2 months; 3 months; 5 months; 8 months; 10 months; 12 months
|
|
Change in low-density lipoprotein cholesterol (LDL) using LDL measurement
Time Frame: baseline; 6 months; 12 months
|
baseline; 6 months; 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sharon Hull, MD MPH, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
June 11, 2015
First Submitted That Met QC Criteria
June 11, 2015
First Posted (Estimate)
June 15, 2015
Study Record Updates
Last Update Posted (Estimate)
January 24, 2017
Last Update Submitted That Met QC Criteria
January 23, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00063493
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes
-
Microbio Co LtdCompleted
-
University of Malagaclinical professorNot yet recruiting
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
Baqai Institute of Diabetology and EndocrinologyNational Institute for Health Research, United Kingdom; University of York; Aga... and other collaboratorsRecruitingType II Diabetes MellitusPakistan
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Khoo Teck Puat HospitalCompletedType II Diabetes in Subjects BMI 27 to 32Singapore
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
Clinical Trials on Personalized Health Planning Shared Medical Appointment
-
University of ArizonaCompletedPostural Orthostatic Tachycardia SyndromeUnited States
-
Emory UniversityCompletedDiabetes | Pre Diabetes | Behavior, HealthUnited States
-
Peking University Third HospitalActive, not recruitingChronic Obstructive Pulmonary Disease, COPDChina
-
St George Hospital, AustraliaNational Health and Medical Research Council, Australia; The University of... and other collaboratorsUnknownPersonal Health Records | Chronic Medical Conditions | Electronic Medical RecordAustralia
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID); Palo Alto Medical...CompletedHealthy Men Age 50 Who Are Considering PSA ScreeningUnited States
-
Duke UniversityCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus | Health Behavior | Group MeetingsUnited States
-
Johns Hopkins UniversityUniversity of Missouri-Columbia; Centers for Disease Control and PreventionCompletedIntimate Partner ViolenceUnited States
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedPrediabetes | Depressive Symptoms Mild to Moderate in SeverityUnited States
-
University of TabukMinistry of Health, Saudi Arabia; Ein Al-Hayat Medical Complex; The Charitable... and other collaboratorsCompletedColorectal Neoplasms | Colorectal Cancer | Colonic Polyp | Occult BleedingSaudi Arabia
-
Daren K. HeylandTerminated